focus -WSS

focus

author：knowledge 2025-09-03 07:47:41 - browse：7425

A person picking up medication at a drive through pharmacy window – biotech and pharma coverage from STAT — Adobe

On Tuesday morning, the Department of Health and Human Services unveiled its long-awaited list of the 10 medicines that will be subject to price negotiation in 2026 under the Inflation Reduction Act.

This will mark the first time that Medicare, the government program for paying for health care for older Americans, will have any ability to use its vast size to negotiate for lower prices. It’s not yet clear how big the discounts on these 10 drugs will be, or even if the law will hold up to multiple legal challenges from the pharmaceutical industry. It’s also not clear, as critics from the drug industry have noted, whether any savings to the government will be passed on to consumers.

Still, the naming of 10 medicines is a milestone, and a point to start appraising the impact of the law. The landscape here is complicated. No one really knows how the IRA’s price negotiation process will play out over the short and long term, and many companies who had products named were spared in other ways, with products many industry watchers expected to see on the list absent. Here is STAT’s assessment of who has won and lost.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： STAT Readout Newsletter: Today in biotech, life science news

WSS

European regulators recommend Amylyx's ALS drug be rejected

Life sciences deals on track to hit lowest point since 2017

How should state employee insurance handle Wegovy?

Hospitals, health systems can help patients avoid medical debt

VC firm RA Capital starts a new synthetic biology incubator

Ford recalls 870K F

hotspot

focus

focus

The cancer drug shortage isn’t new — and neither are the solutions

'The boss' wants server deleted: New allegations emerge in Trump indictment

Psychedelics group wrestles with new pharma identity

Wellcome Trust names Røttingen as its new CEO

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Stoke drug shows lower activity against childhood epilepsy

After affirmative action ruling, medical educators look to 'holistic review'

What the Wegovy shortage looks like for doctors — and for patients

Bright Health sells Medicare Advantage business to Molina

Hospitals, health systems can help patients avoid medical debt

leisure time

Hospitals, health systems can help patients avoid medical debt

Readout LOUD podcast: Merger Mondays, Ozempic panic

Massive project maps cells in human brain in unprecedented detail

Ford recalls 870K F

Peter Marks talks Operation Warp Speed for Rare Diseases

Wellcome Trust names Røttingen as its new CEO

focus

focus

knowledge

focus